North American Cannabis Industry Growth Set to Explode as a New Era Begins
Palm Beach, FL – (October 17, 2018) — North American demand for legal marijuana is expected to jump dramatically as Canada will officially commenced its legalization of recreational marijuana today. According to the Cannabis Business Plan, recreational cannabis could experience annual revenues north of $8 billion by 2020 in Canada alone. This is forcing industry leaders to reinvest profits into the expansion of cultivation efforts as the consumer base grows and new markets emerge. Additionally, the momentum from other countries around the world, including the United States, is driving the industry forward as well. The upcoming mid-term election will feature cannabis as a prime topic for candidates and voters alike. The billion dollar industry has already exploded, but the growth will only continue to be steady as North America approaches full-recreational legalization. Active companies in the industry making moves to ready that include: Choom™ Holdings Inc. (CSE:CHOO) (OTC:CHOOF), Aphria Inc. (TSX:APH.TO) (OTCQB:APHQF), The Green Organic Dutchman Holdings Ltd. (TSX:TGOD.TO) (OTCQX:TGODF), Cronos Group Inc. (NASDAQ:CRON)(TSX:CRON), TerrAscend Corp. (CSE:TER.CN) (OTCPK:TRSSF).
Choom™ Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) BREAKING NEWS: Choom™, a n emerging adult use cannabis company is pleased to report on this historic date – the legalization of adult use cannabis in Canada and the end of prohibition – that its wholly-owned subsidiary, Specialty Medijuana Products Inc., has received a cultivation license from Health Canada.
October 17, 2018 will go down in Canadian history as the day cannabis was legalized for adult use from coast to coast, ending almost a century of prohibition. Choom is poised to become a major retail player in the adult use cannabis space, with stores scheduled to open across the country.
Choom has secured the rights to 52 retail opportunities across Western Canada and its rapidly expanding Alberta presence now stands at 29 in highly strategic and secure locations, with 14 Development permits and 11 building permits received from the various municipalities. With recently amended regulations in Ontario, Choom has deployed its real estate team throughout the province of Ontario to secure a significant cannabis retail footprint in Canada’s largest adult use market.
Choom™ is executing an aggressive expansion plan to create a significant retail storefront brand in the Canadian adult use market and is committed to developing and acquiring retail stores as a top priority. In all cases, the retail opportunities are subject to all necessary governmental and municipal approvals being granted. This number is expected to grow over the coming months as the Company is currently negotiating additional leases with the intention of submitting applications for retail licenses.
Chris Bogart, CEO of Choom Holdings Inc, comments: “Now that legalization is finally here, we are continuing to aggressively roll out our retail strategy. We see a massive opportunity in the retail market, and our goal is to build Choom into an iconic Canadian retail storefront brand. This officially marks opening day in the adult use cannabis market in Canada, and we look forward to the day when Choom is synonymous with good times with good friends from coast to coast.” Read this and more news for Choom™ at: https://financialnewsmedia.com/news-choo/
Additional industry related developments from around the markets:
Aphria Inc. (TSX:APH.TO) (OTCQB:APHQF) earlier this week announced that it has completed its first shipment of cannabis oil to its Argentina -based subsidiary ABP, S.A. (“ABP” or the “Argentinean Company”), a pharmaceutical import and distribution company. In accordance with a previously announced supply agreement, the Company delivered 1,500 bottles of Aphria’s renowned Rideau CBD oil, which were provided to Hospital de Pediatria Garrahan (“Hospital Garrahan” or the “Hospital”), a leading pediatric hospital located in Buenos Aires , for use in a clinical study focused on treating refractory epilepsy in children. Aphria acquired ABP last month when the Company closed its acquisition of LATAM Holdings Inc. (“LATAM Holdings”), expanding the Company’s global footprint to include a leading presence in Latin America and the Caribbean . ” Argentina will play a foundational role as Aphria cements its leadership in medical cannabis throughout the region,” said Vic Neufeld , Chief Executive Officer of Aphria. “Aphria and ABP, in close partnership with the Argentinean government, continue to advance opportunities for medical cannabis in the country, including the potential for in-country cultivation. We are also proud to support the critical and necessary research being undertaken by Hospital Garrahan on the treatment of refractory epilepsy in children with our Rideau CBD oil.”
The Green Organic Dutchman Holdings Ltd. (TSX:TGOD.TO) (OTCQX:TGODF) on Tuesday announced it has received its medical sales license from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) for its Ancaster, Ontario facility. “As we prepare for our Founders Club product launch in January 2019 , this is a critical step in our path to becoming the global leading organic cannabis brand,” said Brian Athaide , CEO of TGOD. “We have been perfecting our organic grow methodology in Ancaster and are prepared for the Q1 launch to medical patients across Canada followed by the launch in adult use markets in Q2.” “We have been working aggressively on both productive capacity and global distribution,” said John Wren , VP of Operations at TGOD. “In addition to Ancaster , we are currently growing in Valleyfield, Quebec at our breeding facility, Jamaica with our partner Epican and Poland with HemPoland. We are on track to progressively ramp up our production throughout 2019, targeting 195,000 kgs of run-rate capacity by the end of the year. TGOD is securing significant distribution networks in Canada , Europe , Jamaica , and Latin America while scaling operations for medical and adult use markets around the world,” continued Mr. Wren.
Cronos Group Inc. (NASDAQ:CRON)(TSX:CRON) earlier this week announced that it has entered into a sponsored research agreement with the Technion Research and Development Foundation of the Technion – Israel Institute of Technology (“Technion”) to explore the use of cannabinoids and their role in regulating skin health and skin disorders. The preclinical studies will be conducted by Technion over a three-year period and will focus on three skin conditions: acne, psoriasis and skin repair. Research will be led by Technion faculty members Dr. David “Dedi” Meiri, Head, Laboratory of Cancer Biology and Cannabinoid Research and Dr. Yaron Fuchs, Head, Laboratory of Cancer Biology and Cannabinoid Research, two of the world’s leading researchers in cannabis and skin stem cell research, respectively. Dr. Meiri heads the Laboratory of Cannabis and Cancer Research with vast experience in cannabis and endocannabinoid research. Dr. Fuchs heads the Laboratory of Stem Cell Biology and Regenerative Medicine with years of experience in the biology of the skin and its pathologies. Development and implementation of the research will be conducted at Technion’s Laboratory of Cancer Biology and Cannabis Research and the Lorry I. Lokey Interdisciplinary Center of Life Sciences and Engineering in Haifa, Israel.
TerrAscend Corp. (CSE:TER.CN) (OTCPK:TRSSF) recently announced that its subsidiary TerrAscend Canada Inc. has entered into a multi-year cultivation agreement with PharmHouse Inc. (“PharmHouse”), a joint venture between Canopy Rivers Inc. (RIV.V) (“Canopy Rivers”) and the principals and operators of a leading North American greenhouse produce company. Under the terms of the agreement, PharmHouse will grow and supply cannabis to TerrAscend Canada from an existing 1.3 million square foot greenhouse (“Facility”), located in Leamington , Ontario. Once fully licensed, the production of flower, trim and clones from 20% of the dedicated flowering space at the Facility will be made available to TerrAscend Canada. TerrAscend Canada may provide proprietary genetic strains to PharmHouse and help oversee production in conjunction with their operators and quality assurance professionals. Cultivation is anticipated to commence in 2019, subject to receipt by PharmHouse of all applicable regulatory licenses and approvals.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by Choom™ Holdings Inc. by a non affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757